Fabrication of β-glucan nanocarriers for enhanced encapsulation and delivery of doxorubicin for triple negative breast cancer treatment.

In this study, beta glucan nanoparticles were fabricated and encapsulated with Doxorubicin for an effective drug delivery for triple negative breast cancer treatment. The synthesized nanoparticles were characterized by FTIR, TEM, SEM, DLS, and zeta potential analysis. A drug encapsulation rate of 80% was achieved and drug release studies displayed a better release of drug from encapsulated glucan nanoparticles in acidic media. In vitro cytotoxicity and cellular uptake were evaluated by MTT and fluorescence microscopy, respectively where the IC50 concentrations for Dox and Dox loaded nano glucans were found to be 2.5 and 1 µg/mL, respectively. SEM, TEM, and DLS results showed that beta glucan nanoparticles have a size distribution between 30-100 nm. FTIR and zeta potential analysis confirmed the loading of Dox. The results over MDA-MB-231 cells showed that Dox loaded beta glucan nanoparticles were effectively internalized and had more cytotoxic activity with respect to free drug.